about
Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantationEvidence against T-cell development in the adult human intestinal mucosa based upon lack of terminal deoxynucleotidyltransferase expressionPreclinical regulatory validation of a 3-stage amniotic mesenchymal stem cell manufacturing protocolHuman acute stem cell leukemia with multilineage differentiation potential via cascade activation of growth factor receptorsActivation of a novel human transforming gene, ret, by DNA rearrangementAberrant expression of SALL4 in acute B cell lymphoblastic leukemia: mechanism, function, and implication for a potential novel therapeutic targetProbing circulating tumor cells in microfluidics.CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemiaLow dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission.Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction.Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells.Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.White blood cell recovery after allogeneic hematopoietic cell transplantation predicts clinical outcome.Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliteransAltered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation.MicroRNA expression profiling identifies activated B cell status in chronic lymphocytic leukemia cells.Angiogenic Factors Correlate with T Cell Immune Reconstitution and Clinical Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults.Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia.Time to put the CAR-T before the horse.Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantationDouble umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis.Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.Identification of cytolytic CD161- CD56+ regulatory CD8 T cells in human peripheral bloodA modified γ-retrovirus vector for X-linked severe combined immunodeficiency.Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantationAdult hematopoietic stem cell plasticity.Factors associated with bronchiolitis obliterans syndrome and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation.Allogeneic stem cell transplantation for multiple myeloma.Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.Aberrant B-cell homeostasis in chronic GVHDLymphokine-activated killer cell activity Characteristics of effector cells and their progenitors in blood and spleen.Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation.Angiogenic cytokines are antibody targets during graft-versus-leukemia reactions.A clonal model for human CD8+ regulatory T cells: unrestricted contact-dependent killing of activated CD4+ T cells.IL-7 and SCF Levels Inversely Correlate with T Cell Reconstitution and Clinical Outcomes after Cord Blood Transplantation in Adults.Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survivalDonor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliteransTargeting Syk-activated B cells in murine and human chronic graft-versus-host disease.Biologic Activity of Autologous, Granulocyte-Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma VaccinesIncreased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation.
P50
Q24537575-8855B794-43EE-4983-BCE7-3A64F5CE97AFQ24541454-A95B9E4C-8F19-4F7B-B6C8-A738F15CF97AQ24655823-FE7488DE-D930-4858-985C-73D0DE01CF30Q28201493-7CF234DD-6D00-451F-BFDA-DC78F65475A2Q28286635-BAD8ACA1-7114-4F38-9D82-F7E2811421B8Q28306608-97C36D9F-59C9-4633-B24F-96DB4D212B9BQ30440019-79249747-D257-4784-8FE6-9E8600B3C215Q30679410-84A8C478-E2D3-4D96-9023-DFD16C91F97FQ33380959-3B918061-52D9-41DB-88C6-5ABC99F48B7BQ33384384-D3D1F5D2-DCC9-4767-9CF3-7122B3B73889Q33526746-FE3DB580-F88A-4736-B7EB-A2A50AD55DADQ33591867-43C410E7-2C42-453A-B6A4-1C3BA48CBE20Q33650918-6202873F-8720-4AE2-BDCF-F52BA50C2C3EQ33781179-F74AC6BA-6EDC-41DB-B56B-BE421A2952DDQ33815631-8177DCD3-B577-4335-ABF7-C5D04AAA1194Q33847322-D5227352-A889-46A0-BDAF-033E34EB61A2Q33847973-DC2818E1-F9F5-4396-9E18-47B43A921B1CQ33917224-5A4AE263-7427-440B-9DF8-FCE6E4AB5E24Q34230116-26AA1C2B-5FF3-4EC8-83B0-38C5A68907AAQ34396189-0D5138DE-CEDE-4DCE-B89F-ECF2BC4152ACQ34451427-46F7DF99-C0F8-4D79-BF82-F7A9346F45C2Q34577019-5DB0DF1D-E278-4C51-801B-8E4B88FF9119Q34635285-9F6946D8-8A71-46E2-A667-CAAD2D5D7E82Q34763502-066B8402-7926-4762-8E40-73048CCCCF20Q34827332-11A1F1B0-2C44-4B82-8B77-6448BF01313FQ34973175-45B9F955-A933-4665-923B-2555634316A1Q35038942-7909CAD1-2159-48EC-A13C-FB98F22AC24EQ35077757-6F897BE3-36EF-4A36-BC9E-45658BE671A2Q35140097-EDAC5924-6F83-442D-8E25-573FC8B7D90AQ35171251-5A17C5A4-9E75-44C7-BA90-84692A613464Q35308776-16B261E3-B22A-4853-A3FA-7DBCF6E73019Q35525729-70E1E7B0-5CBF-4923-8FA6-FEAFE3F21040Q35533586-3BB15270-F43E-4C7B-A76D-C8730DF7963AQ35652928-9EFCA15D-697A-4CCB-9898-6BE1819B74D1Q35692767-E37A8B7E-11F7-4080-A6AB-6AC9FEE636F4Q35769347-5A9967E9-EF56-48C9-8FEE-FAFCFBE6B3FFQ35776453-EACED34D-94EA-41AB-8F51-D71711226B0BQ35784522-43786DB3-A335-4B23-8AB7-17FE3C471094Q35862728-5F1B757E-F05E-48CB-9618-95AC7B213FAEQ36036340-751419E3-C34A-4C75-9026-5050816901A5
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jerome Ritz
@ast
Jerome Ritz
@en
Jerome Ritz
@es
Jerome Ritz
@nl
Jerome Ritz
@sl
type
label
Jerome Ritz
@ast
Jerome Ritz
@en
Jerome Ritz
@es
Jerome Ritz
@nl
Jerome Ritz
@sl
prefLabel
Jerome Ritz
@ast
Jerome Ritz
@en
Jerome Ritz
@es
Jerome Ritz
@nl
Jerome Ritz
@sl
P1053
C-7929-2009
P106
P21
P31
P3829
P496
0000-0001-5526-4669